Consistent with its ability to repress gastrin gene expression (14), a heterozygous MEN1 variant and two heterozygous mutations were identified in all patients diagnosed with duodenal and pancreatic gastrinomas in our previously published cohort (20). This evidence concerns the gene GAST and gastrin-producing neuroendocrine tumor.